drugset / Trial / NCT06057948

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

NCT06057948

Phase 2 Recruiting 94 enrolled Memorial Sloan Kettering Cancer Center
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to test which treatment schedule of β-glucan with bivalent vaccine is more effective for participants with high-risk neuroblastoma that is in complete remission.

Timeline

Start
2023-09-21
Primary completion
2027-03-21
Completion
2027-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject β-glucan Other / unclassified 40 mg/kg Oral
Background OBI-821 Other / unclassified

Indications